172 related articles for article (PubMed ID: 8970471)
1. Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines.
Longini IM; Datta S; Halloran ME
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Dec; 13(5):440-7. PubMed ID: 8970471
[TBL] [Abstract][Full Text] [Related]
2. Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy.
Datta S; Halloran ME; Longini IM
Stat Med; 1998 Jan; 17(2):185-200. PubMed ID: 9483728
[TBL] [Abstract][Full Text] [Related]
3. A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines.
Longini IM; Hudgens MG; Halloran ME; Sagatelian K
Stat Med; 1999 Jan; 18(1):53-68. PubMed ID: 9990692
[TBL] [Abstract][Full Text] [Related]
4. Measuring HIV vaccine efficacy.
Hernández-Suárez CM
Stat Med; 2005 Apr; 24(7):983-92. PubMed ID: 15568204
[TBL] [Abstract][Full Text] [Related]
5. Assessing the effect of HIV vaccination on infectiousness.
Rida WN
Stat Med; 1996 Nov 15-30; 15(21-22):2393-404; discussion 2405-12. PubMed ID: 8931209
[TBL] [Abstract][Full Text] [Related]
6. On the analysis of viral load endpoints in HIV vaccine trials.
Hudgens MG; Hoering A; Self SG
Stat Med; 2003 Jul; 22(14):2281-98. PubMed ID: 12854093
[TBL] [Abstract][Full Text] [Related]
7. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
Adis International Ltd
Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
[TBL] [Abstract][Full Text] [Related]
8. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB
PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672
[TBL] [Abstract][Full Text] [Related]
9. Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trials.
Golm GT; Halloran ME; Longini IM
Biometrics; 1999 Mar; 55(1):94-101. PubMed ID: 11318183
[TBL] [Abstract][Full Text] [Related]
10. Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy.
Gilbert PB
Stat Med; 2001 Jan; 20(2):263-79. PubMed ID: 11169601
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic vaccine trails in Thailand.
Churdboonchart V
J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
[TBL] [Abstract][Full Text] [Related]
12. Semi-parametric models for mismeasured exposure information in vaccine trials.
Golm GT; Halloran ME; Longini IM
Stat Med; 1998 Oct; 17(20):2335-52. PubMed ID: 9819831
[TBL] [Abstract][Full Text] [Related]
13. Some important issues in the planning of phase III HIV vaccine efficacy trials.
Boily MC; Mâsse BR; Desai K; Alary M; Anderson RM
Vaccine; 1999 Feb; 17(7-8):989-1004. PubMed ID: 10067708
[TBL] [Abstract][Full Text] [Related]
14. Some statistical issues in HIV vaccine trials.
Rida WN; Lawrence DN
Stat Med; 1994 Oct 15-30; 13(19-20):2155-77. PubMed ID: 7846417
[TBL] [Abstract][Full Text] [Related]
15. Some statistical issues in the design of HIV-1 vaccine and treatment trials.
Gilbert PB
Stat Methods Med Res; 2000 Jun; 9(3):207-29. PubMed ID: 11084705
[TBL] [Abstract][Full Text] [Related]
16. HIV Vaccine Efficacy Trials: RV144 and Beyond.
Heger E; Schuetz A; Vasan S
Adv Exp Med Biol; 2018; 1075():3-30. PubMed ID: 30030787
[TBL] [Abstract][Full Text] [Related]
17. Chop-lump tests for vaccine trials.
Follmann D; Fay MP; Proschan M
Biometrics; 2009 Sep; 65(3):885-93. PubMed ID: 19210727
[TBL] [Abstract][Full Text] [Related]
18. Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials.
Hudgens MG
Stat Med; 2003 Feb; 22(3):463-79. PubMed ID: 12529875
[TBL] [Abstract][Full Text] [Related]
19. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya.
Jackson DJ; Martin HL; Bwayo JJ; Nyange PM; Rakwar JP; Kashonga F; Mandaliya K; Ndinya-Achola JO; Kreiss JK
AIDS; 1995 Nov; 9(11):1279-83. PubMed ID: 8561982
[TBL] [Abstract][Full Text] [Related]
20. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
Trials; 2014 Feb; 15():68. PubMed ID: 24571662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
